Genetically engineered vaccinia viruses
AssigneesAstellas Pharma Inc., National University Corporation Tottori University
InventorsTakafumi Nakamura, Hajime KUROSAKI, Motomu NAKATAKE
Life of this patent
Estimating the term…
Abstract
The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
Claims20
A vaccinia virus lacking functions of vaccinia virus growth factor (VGF) and O1L and having a gene encoding B5R in which an SCR (short consensus repeat) domain has been deleted.
Dependencies are inferred from the claim text.